AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38663582
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified in detail, but implied to be standard treatment without dose escalation).
Trial: 38663950
Drug: Total carrageenans
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total carrageenans (100 mg per day)
Trial: 38663950
Drug: Carrageenans gum
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenans gum (E407, 100 mg per day)
Trial: 38663950
Drug: Tripotassium phosphate
RxNorm normalized name: dipotassium
DrugBank: Dipotassium phosphate (DB09414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium phosphate (E340, 500 mg per day)
Trial: 38663950
Drug: Acetyl tartaric
RxNorm normalized name: Tartaric Acid
DrugBank: L-tartaric acid (DB09459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetyl tartaric acid esters of monoglycerides and diglycerides of fatty acids (E472e, 100 mg per day)
Trial: 38663950
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (E331, 500 mg per day)
Trial: 38663950
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (E412, 500 mg per day)
Trial: 38663950
Drug: Gum arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum arabic (E414, 1000 mg per day)
Trial: 38663950
Drug: Xanthan gum
RxNorm normalized name: Xanthan Gum
DrugBank: Xanthan gum (DB11253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthan gum (E415, 500 mg per day)
Trial: 38664766
Drug: MTX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX plus corticosteroids (5 mg/m2 methotrexate)
Trial: 38665252
Drug: Combination naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination naltrexone (NTX) and oral bupropion (BUP)
Trial: 38665302
Drug: Mango Leaf
RxNorm normalized name: mango leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mango Leaf Extract (MLE) 300 mg
Trial: 38668005
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care foams
Trial: 38668005
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care spray
Trial: 38668005
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no oral care product)
Trial: 38669053
Drug: Avelumab 800
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 800 mg + chemotherapy (cisplatin + gemcitabine)
Trial: 38669053
Drug: Avelumab 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab 1,200 mg + chemotherapy (cisplatin + gemcitabine)
Trial: 38669053
Drug: Avelumab 800
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 800 mg + chemotherapy (carboplatin + pemetrexed)
Trial: 38669053
Drug: Avelumab 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab 1,200 mg + chemotherapy (carboplatin + pemetrexed)
Trial: 38669354
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of L9LS
Trial: 38669354
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of L9LS
Trial: 38669638
Drug: Erenumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (140 mg once monthly for 3 years)
Trial: 38669638
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by Erenumab (140 mg once monthly for 3 years)
Trial: 38670599
Drug: Acyclovir therapy
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir therapy (specific dosage and duration not mentioned)
Trial: 38671251
Drug: Remimazolam, bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam, bolus dose starting at 0.3 mg·kg
Trial: 38671587
Drug: tislelizumab +
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab + chemotherapy
Trial: 38672531
Drug: Bortezomib addition
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib addition to standard chemotherapy
Trial: 38675738
Drug: TAPCells-based vaccination
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAPCells-based vaccination therapy
Trial: 38675784
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals between February 2021 and June 2021.
Trial: 38675784
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals.
Trial: 38676324
Drug: Electrical dry
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical dry needling and thrust manipulation plus multimodal physical therapy
Trial: 39436270
Drug: Multimodal physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal physical therapy alone
Trial: 38676659
Drug: Cat food
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cat food containing anti-Fel d 1 IgY antibodies
Trial: 38676683
Drug: Divozilimab (DIV)
RxNorm normalized name: divozilimab
DrugBank: Divozilimab (DB18878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divozilimab (DIV) 500 mg
Trial: 38676683
Drug: Teriflunomide (TRF)
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Teriflunomide (TRF) 14 mg
Trial: 38677235
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy Intervention (FREE)
Trial: 38677300
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral drugs
Trial: 38677720
Drug: OP-724 intravenous
RxNorm normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: OP-724 intravenous infusion at doses of 140 or 280 mg/m
Trial: 38678093
Drug: R-HAD +
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-HAD + B (rituximab, high-dose cytarabine, dexamethasone with bortezomib)
Trial: 38678093
Drug: R-HAD (rituximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-HAD (rituximab, high-dose cytarabine, dexamethasone without bortezomib)
Trial: 38678451
Drug: 38% SDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% SDF gel and 2.5% sodium fluoride varnish
Trial: 38678757
Drug: iNAP® Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNAP® Sleep Therapy System
Trial: 38679035
Drug: Vaccinee group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinee group (tetravalent dengue purified inactivated vaccine prime followed by live-attenuated vaccine boost)
Trial: 38679140
Drug: Telephone-delivered motivational
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered motivational interviewing (MI) engagement session and 8 sessions of MI-Cognitive Behavioral Therapy (MI-CBT)
Trial: 38679140
Drug: Enhanced usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced usual care (EUC) involving AUD psychoeducation, advice to reduce drinking and seek treatment, and provision of community resources
Trial: 38679416
Drug: Transperineal prostate
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transperineal prostate biopsy under local anaesthesia (LA) using 40 mL 1% lidocaine with 4 mL of 8.4% sodium bicarbonate.
Trial: 38679697
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention promoting deprescribing of antidepressants
Trial: 38679727
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs)
Trial: 38680067
Drug: 14-day tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day tailored PCR-guided triple therapy (esomeprazole 40 mg, amoxicillin 1000 mg b.d., clarithromycin 500 mg or levofloxacin 500 mg b.d.)
Trial: 38680067
Drug: 14-day non-Bismuth
RxNorm normalized name: bismuth subcitrate 14 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day non-Bismuth concomitant quadruple therapy (esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg b.d.)
Trial: 38680067
Drug: 14-day tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day tailored PCR-guided triple therapy
Trial: 38680067
Drug: 14-day non-Bismuth
RxNorm normalized name: bismuth subcitrate 14 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day non-Bismuth concomitant quadruple therapy
Trial: 38680067
Drug: Economic analysis
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Economic analysis of tailored PCR-guided triple therapy
Trial: 38681788
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen treatment (HFOT) through tracheostomy
Trial: 38682205
Drug: Low-fat yogurt
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat yogurt enriched with Platelet-Activating Factor receptor (PAF-R) antagonists (150 g daily)
Trial: 38683027
Drug: Crushed 200-mg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed 200-mg cenobamate tablet administered orally
Trial: 38683027
Drug: Crushed 200-mg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed 200-mg cenobamate tablet administered via nasogastric tube
Trial: 38683027
Drug: Intact 200-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact 200-mg cenobamate tablet
Trial: 38683596
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg once daily for 5 years
Trial: 38683596
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 5 years
Trial: 38683966
Drug: HA-1 TCR-T
RxNorm normalized name: NY-ESO-1 TCR T
DrugBank: Letetresgene autoleucel (DB17233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1 TCR-T therapy after lymphodepleting chemotherapy
Trial: 38684039
Drug: Unesbulin 300
RxNorm normalized name: Unesbulin
DrugBank: Unesbulin (DB18080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unesbulin 300 mg administered orally twice per week plus DTIC 1,000 mg/m
Trial: 38684046
Drug: Dutasteride 1
RxNorm normalized name: dutasteride 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 1 mg daily for 12 weeks
Trial: 38684080
Drug: Patient partnership
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient partnership tools including a 1-page visit preparation guide and a library of short educational videos on medication safety.
Trial: 38684243
Drug: Norepinephrine (dilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (dilution to 0.016 mg/mL) using an electric syringe pump at a rate of 0.48 mg/h (30 mL/h) from the start of anaesthesia, titrated to achieve haemodynamic target.
Trial: 38684243
Drug: Ephedrine, manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine, manual titration with a maximal dose of 30 mg, followed by perfusion with norepinephrine.
Trial: 38684260
Drug: Maternal nightly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal nightly positional therapy (PT)
Trial: 38684260
Drug: Sham positional
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham positional therapy (sham-PT)
Trial: 38684265
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (oral Vitamin D3 50,000 IU/week for 4 weeks, then 50,000 IU once every 2 weeks for 52 weeks)
Trial: 38684276
Drug: Independently taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independently taking lethal medication attended by a confidant (ILMC)
Trial: 38684631
Drug: Lovo-cel gene
RxNorm normalized name: Lovo-cel
DrugBank: Lovotibeglogene autotemcel (DB18680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovo-cel gene therapy
Trial: 38684670
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment regimen for high-risk SMM patients
Trial: 38684670
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment regimen for ultra-high risk (UHR) SMM patients
Trial: 38685017
Drug: Outpatient Parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient Parenteral Antimicrobial Therapy (OPAT)
Trial: 38685109
Drug: MMS for
RxNorm normalized name: Gas for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMS for 180 days with one 180-count tablet bottle (MMS-180)
Trial: 38685109
Drug: MMS for
RxNorm normalized name: Gas for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMS for 180 days with two distributions of 90-count tablet bottles (MMS-90)
Trial: 38685119
Drug: Women receiving
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women receiving chemotherapy
Trial: 38685119
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who previously delayed breast cancer treatment more than 3 months
Trial: 38685376
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of life-sustaining therapies (WLST)
Trial: 38685481
Drug: 2-g out-of-hospital
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-g out-of-hospital TXA bolus
Trial: 38685481
Drug: 1-g out-of-hospital
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion
Trial: 38685481
Drug: Out-of-hospital saline
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-hospital saline bolus/in-hospital saline infusion (placebo)
Trial: 38685704
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by four titanium-zirconium mini implants
Trial: 38685927
Drug: iTalkBetter (self-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iTalkBetter (self-led app utilizing confrontation naming therapy)
Trial: 38685972
Drug: inetetamab and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inetetamab and pyrotinib (240 mg, 320 mg)
Trial: 38686016
Drug: Dato-DXd monotherapy
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dato-DXd monotherapy
Trial: 38686016
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of therapy (ICT; capecitabine, pembrolizumab, or capecitabine and pembrolizumab)
Trial: 38686365
Drug: Sugammadex (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2 mg/kg) administered intravenously post-surgery
Trial: 38686450
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 mcg bd daily for 4 weeks
Trial: 38686879
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor inhibitor initiation
Trial: 38687061
Drug: Probiotic intervention
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic intervention (mixture of four probiotic strains with galacto-oligosaccharides) administered to mothers from the 36th week of pregnancy and to infants until 6 months of age.
Trial: 38687136
Drug: E-cigarette inhalation
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-cigarette inhalation
Trial: 38687339
Drug: Direct Cold
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Cold Atmospheric Plasma treatment, applied once or twice a week
Trial: 38687481
Drug: 0.4-mg aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4-mg aflibercept injection
Trial: 38687693
Drug: Educational training
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational training by a multidisciplinary team at hospital discharge and follow-up phone recall for therapy adherence.
Trial: 38687741
Drug: Schroth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schroth treatment (Standard care + Schroth treatment)
Trial: 38688118
Drug: Subcutaneous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ketamine (0.5 mg/kg, adjusted according to individual responses)
Trial: 38688665
Drug: Low-dose metformin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metformin (500 mg two times per day)
Trial: 38688665
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (1000 mg two times per day)
Trial: 38688675
Drug: Dextromethorphan 30
RxNorm normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 30 mg once daily as an add-on to ongoing SSRI treatment for 8 weeks
Trial: 38688675
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily as an add-on to ongoing SSRI treatment for 8 weeks
Trial: 38688675
Drug: Dextromethorphan 30
RxNorm normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 30 mg once daily
Trial: 38688998
Drug: Intranasal parent's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal parent's own milk (IPOM), given ideally twice daily until 28 days of age.
Trial: 38689167
Drug: Self-assessment questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-assessment questionnaires about CRF, sleep disturbances, and emotional symptoms; accelerometer for physical activity and sleep quality; cognitive, neuromuscular, and exercise metabolism evaluations.
Trial: 38689256
Drug: Concentrated exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated exposure treatment (cET) delivered during four consecutive days
Trial: 38689269
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ddPCR with multiparameter flow cytometry (MFC)
Trial: 38689304
Drug: Targeted BEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted BEP supplementation based on baseline nutritional status and monthly gestational weight gain monitoring (Arm 3)
Trial: 38689324
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy treatments (up to five massages within a 4-month period)
Trial: 38689324
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy treatments
Trial: 38689402
Drug: Subdissociative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdissociative ketamine infusion (KI)
Trial: 38690606
Drug: AZD9567 72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9567 72 mg daily
Trial: 38690606
Drug: AZD9567 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9567 40 mg daily
Trial: 38690606
Drug: Prednisolone 20
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 20 mg daily
Trial: 38690733
Drug: Balance disruption
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance disruption between IFN-stimulated genes and IFN inhibitors.
Trial: 38691209
Drug: Leucocyte-platelet-rich fibrin
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-platelet-rich fibrin (L-PRF) with coronally advanced flap (CAF)
Trial: 38691316
Drug: Palopegteriparatide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palopegteriparatide treatment